The Top Venture-Capital Investors in the Psychedelics Industry businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
UK sees its first VC fund for psychedelic treatments of depression Dec 21, 2020 By Funds Europe
The UK’s first venture capital fund devoted to “psychedelic healthcare” was launched last week and will invest in “revolutionary mind-altering medicines” to treat illnesses including depression, addiction, anxiety and inflamation.
Neo Kuma Ventures launched the fund and said it had already attracted millions of pounds in investment. The fund continues to fund raise through the first half of 2021.
The firm, which was only founded in 2019, claimed recent “rigorous clinical trials” had demonstrated the potential of psychedelics’ to treat mental illnesses including post-traumatic stress disorder (PTSD), depression, addiction and anxiety.
First psychedelic healthcare fund launches in Britain
A new fund has launched in Britain that will allow investors to put their money into mind altering drugs to be used for medical purposes. (Getty Images)
Britain’s first investment fund dedicated solely to psychedelic healthcare launched this week, allowing investors to put money into mind altering drugs for medical use.
The fund, launched by London-based venture capital firm Neo Kuma, has an investment thesis focused on clinically proven psychedelic medicines that it believes will hit the market in the next five years.
The launch comes after clinical trials have demonstrated the potential of psychedelic drugs to treat needs in mental illness, including post-traumatic stress disorder, depression, addiction and anxiety.
Britain s first psychedelic healthcare fund ifamagazine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ifamagazine.com Daily Mail and Mail on Sunday newspapers.
17 Dec 2020 Share:
More and more revolutionary mind-altering medicines and treatments based on active ingredients previously spurned as street drugs, such as ketamine and psilocybin (magic mushrooms), are gaining acceptance with regulators. Clinical trials show psychedelics have huge potential to help people with treatment resistant mental illnesses including depression, addiction, anxiety and inflammation. So, with the launch of its first investment fund, will the psychedelic healthcare sector run at the heels of the medicinal cannabis industry and enable Europe to become the new hub of a burgeoning market sector?
The UK s first investment fund dedicated solely to psychedelic healthcare has launched.